Next Article in Journal
Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality
Next Article in Special Issue
Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis
Previous Article in Journal
Tumor-Promoting Circuits That Regulate a Cancer-Related Chemokine Cluster: Dominance of Inflammatory Mediators Over Oncogenic Alterations
Cancers 2012, 4(1), 77-87; doi:10.3390/cancers4010077
Review

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas

Received: 7 December 2011; in revised form: 17 January 2012 / Accepted: 18 January 2012 / Published: 1 February 2012
View Full-Text   |   Download PDF [109 KB, uploaded 1 February 2012]   |   Browse Figure
Abstract: Malignant gliomas account for approximately 60% of all primary brain tumors in adults. The prognosis for patients with malignant glioma has not changed significantly in recent years. Despite debulking surgery, radiotherapy and cytotoxic chemotherapy, the median survival time is nine to 12 months, and very few, if any, patients are cured from this illness. Fotemustine is an alkylating agent characterized by the grafting of a phosphonoalanine group onto the nitrosourea radical with consequent high lipophilicity and improved diffusion through the cell membrane and the blood-brain barrier. Fotemustine has been registered for use in two indications: disseminated malignant melanoma, including cerebral metastases, and primary brain tumors. Fotemustine is currently used in Europe, particularly in France and Italy, as a salvage therapy for recurrent malignant gliomas. Myelosuppression, leucopenia and thrombocytopenia are the most frequent side effects of treatment with fotemustine. The objective response to this treatment is between 26% and 70%, and the reported median survival time is 10 months. New drug combinations containing fotemustine and angiogenesis inhibitors, such as bevacizumab, are currently under development. In this review, we describe all the combinations of fotemustine currently used in clinical practice for recurrent malignant gliomas.
Keywords: malignant gliomas; recurrent tumors; chemotherapy; fotemustine; salvage therapy; second-line treatment malignant gliomas; recurrent tumors; chemotherapy; fotemustine; salvage therapy; second-line treatment
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Beauchesne, P. Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas. Cancers 2012, 4, 77-87.

AMA Style

Beauchesne P. Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas. Cancers. 2012; 4(1):77-87.

Chicago/Turabian Style

Beauchesne, Patrick. 2012. "Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas." Cancers 4, no. 1: 77-87.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert